Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Neurology and Neuroscience Reports
Published in: Current Neurology and Neuroscience Reports 11/2022

03-10-2022 | Amyotrophic Lateral Sclerosis | Dementia (K.S. Marder, Section Editor)

Limbic-Predominant Age-Related TDP-43 Encephalopathy: LATE-Breaking Updates in Clinicopathologic Features and Biomarkers

Authors: Michael Tran Duong, David A. Wolk

Published in: Current Neurology and Neuroscience Reports | Issue 11/2022

Login to get access

Abstract

Purpose of Review

Limbic-predominant age-related TDP-43 encephalopathy (LATE) is a recently defined neurodegenerative disease characterized by amnestic phenotype and pathological inclusions of TAR DNA-binding protein 43 (TDP-43). LATE is distinct from rarer forms of TDP-43 diseases such as frontotemporal lobar degeneration with TDP-43 but is also a common copathology with Alzheimer’s disease (AD) and cerebrovascular disease and accelerates cognitive decline. LATE contributes to clinicopathologic heterogeneity in neurodegenerative diseases, so it is imperative to distinguish LATE from other etiologies.

Recent Findings

Novel biomarkers for LATE are being developed with magnetic resonance imaging (MRI) and positron emission tomography (PET). When cooccurring with AD, LATE exhibits identifiable patterns of limbic-predominant atrophy on MRI and hypometabolism on 18F-fluorodeoxyglucose PET that are greater than expected relative to levels of local AD pathology. Efforts are being made to develop TDP-43-specific radiotracers, molecularly specific biofluid measures, and genomic predictors of TDP-43. LATE is a highly prevalent neurodegenerative disease distinct from previously characterized cognitive disorders.
Literature
1.••
Nelson PT, Dickson DW, Trojanowski JQ, et al. Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain. 2019;142(6):1503–27 (Important paper from a consensus panel that establishes recommendations for diagnosing LATE.).PubMedPubMedCentralCrossRef
2.
Besser LM, Teylan MA, Nelson PT. Limbic predominant age-related TDP-43 encephalopathy (LATE): clinical and neuropathological associations. J Neuropathol Exp Neurol. 2020;79(3):305–13.PubMedCrossRef
3.••
Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314(5796):130–3 (One of the first studies to discover TDP-43 pathology in neurodegenerative diseases, including FTLD and ALS.).PubMedCrossRef
4.••
Arai T, Hasegawa M, Akiyama H, et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun. 2006;351(3):602–11 (One of the first studies to discover TDP-43 pathology in neurodegenerative diseases, including FTLD and ALS.).PubMedCrossRef
5.••
Amador-Ortiz C, Lin W-L, Ahmed Z, et al. TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer’s disease. Ann Neurol. 2007;61(5):435–45 (First study to find TDP-43 inclusions in hippocampal sclerosis and AD.).PubMedPubMedCentralCrossRef
6.•
Nelson PT, Brayne C, Flanagan ME, et al. Frequency of LATE neuropathologic change across the spectrum of Alzheimer’s disease neuropathology: combined data from 13 community-based or population-based autopsy cohorts. Acta Neuropathol. 2022;144(1):27–44 (Updated study determining prevalence of LATE in older adults.).PubMedPubMedCentralCrossRef
7.
Jack CR, Bennett DA, Blennow K, et al. NIA-AA Research Framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14:535–62.PubMedPubMedCentralCrossRef
8.
Meneses A, Koga S, O’Leary J, Dickson DW, Bu G, Zhao N. TDP-43 Pathology in Alzheimer’s disease. Mol Neurodegen. 2021;16:84.CrossRef
9.
Thomas DX, Bajaj S, McRae-McKee K, Hadjichrsanthou C, Anderson RM, Collinge J. Association of TDP-43 proteinopathy, cerebral amyloid angiopathy, and Lewy bodies with cognitive impairment in individuals with or without Alzheimer’s disease neuropathology. Sci Rep. 2020;10:14579.PubMedPubMedCentralCrossRef
10.
Robinson JL, Lee EB, Xie SX, et al. Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated. Brain. 2018;141(7):2181–93.PubMedPubMedCentralCrossRef
11.•
Dickson DW, Davies P, Bevona C, et al. Hippocampal sclerosis: a common pathological feature of dementia in very old (> or =80 years of age) humans. Acta Neuropathol. 1994;88:212–21 (First pathological study to define hippocampal sclerosis, a common neuroanatomical feature in LATE.).PubMedCrossRef
12.
13.
14.
Lopez OL, Kofler J, Chang YF, et al. Hippocampal sclerosis, TDP-43, and the duration of the symptoms of dementia of AD patients. Ann Clin Transl Neurol. 2020;7(9):1546–56.PubMedPubMedCentralCrossRef
15.
Josephs KA, Dickson DW, Tosakulwong N, et al. Rates of hippocampal atrophy and presence of post-mortem TDP-43 in patients with Alzheimer’s disease: a longitudinal retrospective study. Lancet Neurol. 2017;16(11):917–24.PubMedPubMedCentralCrossRef
16.•
Kapasi A, Yu L, Boyle PA, Barnes LL, Bennett DA, Schneider JA. Limbic-predominant age-related TDP-43 encephalopathy (LATE), ADNC pathology, and cognitive decline in aging. Neurology. 2020;95(14):e1951–62 (Recent study on the influence of LATE and AD pathologies on cognitive decline rates.).PubMedPubMedCentralCrossRef
17.•
Gauthreaux KM, Teylan MA, Katsumata Y, et al. Limbic-predominant age-related TDP-43 encephalopathy: medical and pathologic factors associated with comorbid hippocampal sclerosis. Neurology. 2022;98(14):e1422–33 (Important study dissecting the differences in clinical and pathological factors affecting LATE with HS vs. LATE without HS.).PubMedCrossRef
18.
Wilson RS, Yu L, Trojanowski JQ, et al. TDP-43 pathology, cognitive decline, and dementia in old age. JAMA Neurol. 2013;70(11):1418–24.PubMedCrossRef
19.
Josephs KA, Murray ME, Whitwell JL, et al. Staging TDP-43 pathology in Alzheimer’s disease. Acta Neuropathol. 2014;127(3):441–50.PubMedCrossRef
20.
Nag S, Yu L, Boyle PA, Leurgans SE, Bennett DA, Schneider JA. TDP-43 pathology in anterior temporal pole cortex in aging and Alzheimer’s disease. Acta Neuropathol Commun. 2018;6:33.PubMedPubMedCentralCrossRef
21.•
Liu KY, Reeves S, McAleese KE, Attems J, Francis P, Thomas A, Howard R. Neuropsychiatric symptoms in limbic-predominant age-related TDP-43 encephalopathy and Alzheimer’s disease. Brain. 143(12):3842–3849. Important investigation on neurological and psychiatric symptoms in LATE and AD.
22.
Blass DM, Hatanpaa KJ, Rao V, Steinberg M, Troncoso JC, Rabins PV. Dementia in hippocampal sclerosis resembles frontotemporal dementia more than Alzheimer disease. Neurology. 2004;63(3):492–7.PubMedCrossRef
23.
Jo M, Lee S, Jeon YM, Kim S, Kwon Y, Kim HJ. The role of TDP-43 propagation in neurodegenerative diseases: integrating insights from clinical and experimental studies. Exp Mol Med. 2020;52(10):1652–62.PubMedPubMedCentralCrossRef
24.
Cohen TJ, Lee VM-Y, Trojanowski TJ. TDP-43 functions and pathogenic mechanisms implicated in TDP-43 proteinopathies. Trends Mol Med. 2011;17(11):659–667.
25.
Colombrita C, Zennaro E, Fallini C, et al. TDP-43 is recruited to stress granules in conditions of oxidative insult. J Neurochem. 2009;111(4):1051–61.PubMedCrossRef
26.
McGurk L, Gomes E, Guo L, et al. Poly(ADP-ribose) prevents pathological phase separation of TDP-43 by promoting liquid demixing and stress granule localization. Mol Cell. 2018;71(5):703–17.PubMedPubMedCentralCrossRef
27.
Barmada SJ, Skibinski G, Korb E, Rao EJ, Wu JY, Finkbeiner S. Cytoplasmic mislocalization of TDP-43 is toxic to neurons and enhanced by a mutation associated with familial amyotrophic lateral sclerosis. J Neurosci. 2010;30(2):639–49.PubMedPubMedCentralCrossRef
28.
Herzog JJ, Xu W, Deshpande M, et al. TDP-43 dysfunction restricts dendritic complexity by inhibiting CREB activation and altering gene expression. Proc Natl Acad Sci USA. 2020;117(21):11760–9.PubMedPubMedCentralCrossRef
29.
Paolicelli RC, Jawaid A, Henstridge CM, et al. TDP-43 Depletion in microglia promotes amyloid clearance but also induces synapse loss. Neuron. 2017;95:293–308.CrossRef
30.
James BD, Wilson RS, Boyle PA, Trojanowski JQ, Bennett DA, Schneider JA. TDP-43 stage, mixed pathologies, and clinical Alzheimer’s-type dementia. Brain. 2016;139(11):2983–93.PubMedPubMedCentralCrossRef
31.
Porta S, Xu Y, Lehr T, et al. Distinct brain-derived TDP-43 strains from FTLD-TDP subtypes induce diverse morphological TDP-43 aggregates and spreading patterns in vitro and in vivo. Neuropathol Appl Neurobiol. 2021;47(7):1033–49.PubMedCrossRef
32.
Tan RH, Ke YD, Ittner LM, Halliday GM. ALS/FTLD: experimental models and reality. Acta Neuropathol. 2017;133(2):177–96.PubMedCrossRef
33.
de Boer EMJ, Orie VK, Williams T, et al. TDP-43 proteinopathies: a new wave of neurodegenerative diseases. J Neurol Neurosurg Psychiatry. 2021;92:86–95.CrossRef
34.
Niccoli T, Partridge L, Isaacs AM. Ageing as a risk factor for ALS/FTD. Hum Mol Genet. 2017;26(R2):R105–13.PubMedCrossRef
35.
Robinson JL, Porta S, Garrett FG, et al. Limbic-predominant age-related TDP-43 encephalopathy differs from frontotemporal lobar degeneration. Brain. 2020;143(9):2844–57.PubMedPubMedCentralCrossRef
36.
Wider C, Dickson DW, Stoessl AJ, et al. Pallidonigral TDP-43 pathology in Perry syndrome. Parkinsonism Relat Disord. 2009;15(4):281–6.PubMedCrossRef
37.•
Dickson DW, Baker M, Rademakers R. Common variant in GRN is a genetic risk factor for hippocampal sclerosis in the elderly. Neurodegenerative Dis. 2010;7:170–4 (One of the first inquiries into genetic risk for hippocampal sclerosis.).CrossRef
38.
39.
Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA. 1993;90(5):1977–81.PubMedPubMedCentralCrossRef
40.
Wolk DA, Dickerson BC. Alzheimer’s disease neuroimaging initiative. Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimer’s disease. Proc Natl Acad Sci USA. 2010;107(22):10256–61.PubMedPubMedCentralCrossRef
41.
Duong MT, Nasrallah IM, Wolk DA, Chang CCY, Chang T-Y. Cholesterol, atherosclerosis, and APOE in vascular contributions to cognitive impairment and dementia (VCID): potential mechanisms and therapy. Front Aging Neurosci. 2021;13: 647990.PubMedPubMedCentralCrossRef
42.
Yang H-S, Yu L, Whie CC, et al. Evaluation of TDP-43 proteinopathy and hippocampal sclerosis in relation to APOE ε4 haplotype status: a community-based cohort study. Lancet Neurol. 2018;17(9):773–81.PubMedPubMedCentralCrossRef
43.•
Yang H-S, White CC, Klein H-U, et al. Genetics of gene expression in the aging human brain reveal TDP-43 proteinopathy pathophysiology. Neuron. 2020;107:496–508 (Important study that identified several risk loci of TDP-43 proteinopathies.).PubMedPubMedCentralCrossRef
44.
Nelson PT, Estus S, Abner EL, et al. ABCC9 gene polymorphism is associated with hippocampal sclerosis of aging pathology. Acta Neuropathol. 2014;127(6):825–43.PubMedPubMedCentralCrossRef
45.
Dugan AJ, Nelson PT, Katsumata Y, et al. Analysis of genes (TMEM106B, GRN, ABCC9, KCNMB2, and APOE) implicated in risk for LATE-NC and hippocampal sclerosis provides pathogenetic insights: a retrospective genetic association study. Acta Neuropathol Comm. 2021;9:152.CrossRef
46.
Brady OA, Zheng Y, Murphy K, Huang M, Hu F. The frontotemporal lobar degeneration risk factor, TMEM106B, regulates lysosomal morphology and function. Hum Mol Genet. 2013;22(4):685–95.PubMedCrossRef
47.
Gallagher MD, Posavi M, Huang P, et al. A dementia-associated risk variant near TMEM106B alters chromatin architecture and gene expression. Am J Hum Genet. 2017;101(5):643–63.PubMedPubMedCentralCrossRef
48.••
Van Deerlin VM, Sleiman PMA, Martinez-Lage M, et al. Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet. 2010;42(3):234–9 (First study to map the genetic architecture of TDP-43 disorders.).PubMedPubMedCentralCrossRef
49.••
van der Zee J, Van Langenhove T, Kleinberger G, et al. TMEM106B is associated with frontotemporal lobar degeneration in a clinically diagnosed patient cohort. Brain. 2011;134(Pt 3):808–15 (First study to map the genetic architecture of TDP-43 disorders.).PubMedPubMedCentral
50.
Yu L, De Jager PL, Yang J, Trojanowski JQ, Bennett DA, Schneider JA. The TMEM106B locus and TDP-43 pathology in older persons without FTLD. Neurology. 2015;84(9):927–34.PubMedPubMedCentralCrossRef
51.
Wightman DP, Jansen IE, Savage JE, et al. A genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimer’s disease. Nat Genet. 2021;53:1276–82.PubMedCrossRef
52.
Li Z, Farias FHG, Dube U, et al. The TMEM106B FTLD-protective variant, rs1990621, is also associated with increased neuronal proportion. Acta Neuropathol. 2020;139(1):45–61.PubMedCrossRef
53.
Chang A, Xiang X, Wang J, et al. Homotypic fibrillization of TMEM106B across diverse neurodegenerative diseases. Cell. 2022;185:1–10.CrossRef
54.
Jiang YX, Cao Q, Sawaya MR, et al. Amyloid fibrils in disease FTLD-TDP are composed of TMEM106B not TDP-43. Nature. 2022;605:304–9.PubMedCrossRef
55.
56.
57.
Latimer CS, Burke BT, Liachko NF, et al. Resistance and resilience to Alzheimer’s disease pathology are associated with reduced cortical pTau and absence of limbic-predominant age-related TDP-43 encephalopathy in a community-based cohort. Acta Neuropathol Commun. 2019;7:91.PubMedCrossRef
58.
Shih Y-H, Tu L-H, Chang T-Y, et al. TDP-43 interacts with amyloid-β, inhibits fibrillization, and worsens pathology in a model of Alzheimer’s disease. Nat Commun. 2020;11:5950.PubMedPubMedCentralCrossRef
59.
Katsumata Y, Fardo DW, Kukull WA, Nelson PT. Dichotomous scoring of TDP-43 proteinopathy from specific brain regions in 27 academic research centers: associations with Alzheimer’s disease and cerebrovascular disease pathologies. Acta Neuropathol Comm. 2018;6:142.CrossRef
60.
Raghavan S, Przybelski SA, Reid RI, et al. White matter damage due to vascular, tau, and TDP-43 pathologies and its relevance to cognition. Acta Neuropathol Comm. 2022;10:16.CrossRef
61.
Agrawal S, Yu L, Kapasi A, et al. Limbic-predominant age-related TDP-43 encephalopathy neuropathologic change and microvascular pathologies in community-dwelling older persons. Brain Pathol. 2021;31(3): e12939.PubMedPubMedCentralCrossRef
62.•
Uemura MT, Robinson JL, Cousins KAQ, et al. Distinct characteristics of limbic-predominant age-related TDP-43 encephalopathy in Lewy body disease. Acta Neuropathol. 2022;143(1):15–31 (Recent investigation elucidating the histopathological differences between LATE+LBD and LATE+AD.).PubMedCrossRef
63.
Agrawal S, Yu L, Nag S, et al. The association of Lewy bodies with limbic-predominant age-related TDP-43 encephalopathy neuropathologic changes and their role in cognition and Alzheimer’s dementia in older persons. Acta Neuropathol Commun. 2021;9:156.PubMedPubMedCentralCrossRef
64.
Bayram E, Shan G, Cummings JL. Associations between comorbid TDP-43, Lewy body pathology, and neuropsychiatric symptoms in Alzheimer’s disease. J Alzheimers Dis. 2019;69(4):953–61.PubMedPubMedCentralCrossRef
65.
Nakashima-Yasuda H, Uryu K, Robinson J, et al. Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. Acta Neuropathol. 2007;114(3):221–9.PubMedCrossRef
66.
67.
Makkinejad N, Schneider JA, Yu J, et al. Associations of amygdala volume and shape with transactive response DNA-binding protein 43 (TDP-43) pathology in a community cohort of older adults. Neurobiol Aging. 2019;77:104–11.PubMedPubMedCentralCrossRef
68.•
Ravikumar S, Wisse LEM, Lim S, et al. Ex vivo MRI atlas of the human medial temporal lobe: characterizing neurodegeneration due to tau pathology. Acta Neuropathol Comm. 2021;9:173 (Recent investigation comparing the effects of TDP-43 and tau pathology on MTL thickness on postmortem imaging.).CrossRef
69.•
Wisse LEM, Ravikumar S, Ittyerah R, et al. Downstream effects of polypathology on neurodegeneration of medial temporal lobe subregions. Acta Neuropathol Comm. 2021;9:128 (Recent work to evaluate the contributions of TDP-43, amyloid, tau, and α-synuclein pathology on MTL thickness with ex vivo MRI.).CrossRef
70.•
de Flores R, Wisse LEM, Das SR, et al. Contribution of mixed pathology to medial temporal lobe atrophy in Alzheimer’s disease. Alzheimers Dement. 2020;16(6):843–52 (Important investigation on the effects of TDP-43 and tau pathology on MTL thickness. TDP-43 burden was associated with anterior MTL atrophy.).PubMedPubMedCentralCrossRef
71.
de Flores R, Das SR, Xie L, et al. Medial temporal lobe networks in Alzheimer’s disease: structural and molecular vulnerabilities. J Neurosci. 2022;42(10):2131–41.PubMedPubMedCentralCrossRef
72.
Buciuc M, Martin PR, Tosakulwong N, et al. TDP-43-associated atrophy in brains with and without frontotemporal lobar degeneration. Neuroimage Clin. 2022;34: 102954.PubMedPubMedCentralCrossRef
73.••
Botha H, Mantyh WG, Murray ME, et al. FDG-PET in tau-negative amnestic dementia resembles that of autopsy-proven hippocampal sclerosis. Brain. 2018;141(4):1201–17 (First study to show a distinct 18F-FDG PET pattern for pathologically defined LATE.).PubMedPubMedCentralCrossRef
74.•
Buciuc M, Botha H, Murray ME, et al. Utility of FDG-PET in diagnosis of Alzheimer-related TDP-43 proteinopathy. Neurology. 2020;85:e23–34 (Important study that improves an 18F-FDG PET pattern for LATE and compares this biomarker to structural MRI.).CrossRef
75.
Tanzey S, Brooks A, Shao X, Scott P. Extraction of enriched phosphorylated TDP43 from ALS tissue for evaluation of new TDP-43 radiotracers. J Nucl Med. 2020;61(S1):1038.
76.
Arseni D, Hasegawa M, Murzin AG, Kametani F, Arai M, Yoshida M, Ryskeldi-Falcon B. Structure of pathological TDP-43 filaments from ALS with FTLD. Nature. 2022;601(7891):139–43.PubMedCrossRef
77.
78.
Gómez-Isla T, Hollister R, West H, et al. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer’s disease. Ann Neurol. 1997;41(1):17–24.PubMedCrossRef
79.
Gómez-Isla T, Frosch MP. Lesions without symptoms: understanding resilience to Alzheimer disease neuropathological changes. Nat Rev Neurol 2022;18(6):323–332
80.•
Das SR, Lyu X, Duong MT, et al. Tau-atrophy variability reveals phenotypic heterogeneity in Alzheimer’s disease. Ann Neurol. 2021;90:751–62 (First imaging study to explicitly model the mismatch between tau pathology and neurodegeneration on MRI).PubMedPubMedCentralCrossRef
81.•
Duong MT, Das SR, Lyu X, et al. Dissociation of tau pathology and neuronal hypometabolism within the ATN framework of Alzheimer’s disease. Nat Commun. 2022;13(1):1495 (First PET study to infer non-AD copathologies such as TDP-43 and α-synuclein imaging patterns based on hypometabolism relative to AD tau accumulation.).PubMedPubMedCentralCrossRef
82.
Goossens J, Vanmechelen E, Trojanowski JQ, et al. TDP-43 as a possible biomarker for frontotemporal lobar degeneration: a systematic review of existing antibodies. Acta Neuropathol Comm. 2015;3:15.CrossRef
83.•
Foulds P, McAuley E, Gibbons L, et al. TDP-43 protein in plasma may index TDP-43 brain pathology in Alzheimer’s disease and frontotemporal lobar degeneration. Acta Neuropathol. 2008;116:141–6 (One of the first papers to detect plasma TDP-43 protein in patients with FTLD and AD. The patients with AD and TDP-43 biomarkers may in fact have mixed LATE with AD.).PubMedPubMedCentralCrossRef
84.•
Steinacker P, Hendrich C, Sperfeld AD, et al. TDP-43 in cerebrospinal fluid of patients with frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Arch Neurol. 2008;65(11):1481–7 (One of the first studies to detect elevated TDP-43 protein in the CSF of patients with TDP-43 pathology.).PubMedPubMedCentralCrossRef
85.
Ren Y, Li S, Chen S, et al. TDP-43 and phosphorylated TDP-43 levels in paired plasma and CSF samples in amyotrophic lateral sclerosis. Front Neurol. 2021;12: 663637.PubMedPubMedCentralCrossRef
86.
Beyers L, Günther R, Koch JC, et al. TDP-43 as structure-based biomarker in amyotrophic lateral sclerosis. Ann Clin Transl Neurol. 2021;8(1):271–7.CrossRef
87.
Majumder V, Gregory JM, Barria MA, Green A, Pal S. TDP-43 as a potential biomarker for amyotrophic lateral sclerosis: a systematic review and meta-analysis. BMC Neurol. 2018;18:90.PubMedPubMedCentralCrossRef
88.
Kasai T, Tokuda T, Ishigami N, et al. Increased TDP-43 protein in cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Acta Neuropathol. 2009;117(1):55–62.PubMedCrossRef
89.
Zhang N, Gu D, Meng M, Gordon ML. TDP-43 is elevated in plasma neuronal-derived exosomes of patients with Alzheimer’s disease. Front Aging Neurosci. 2020;12:166.PubMedPubMedCentralCrossRef
90.
Sun L, Li W, Yue L, Xiao S. Blood TDP-43 combined with demographics information predicts dementia occurrence in community non-dementia elderly. J Alzheimers Dis. 2021;79(1):301–9.PubMedCrossRef
91.•
González AC, Irwin DJ, Alcolea D, et al. Multimarker synaptic protein cerebrospinal fluid panels reflect TDP-43 pathology and cognitive performance in a pathological cohort of frontotemporal lobar degeneration. Mol Neurodegen. 2022;17:29 (Essential study identifying CSF markers of TDP-43 pathology in FTLD-TDP compared to FTLD-Tau and AD.).CrossRef
92.
93.
Benarroch E. What is the role of stathmin-2 in axonal biology and degeneration? Neurology. 2021;97:330–3.PubMedCrossRef
94.
Klim JR, Williams LA, Limone F, et al. ALS-implicated protein TDP-43 sustains levels of STMN2, a mediator of motor neuron growth and repair. Nat Neurosci. 2019;22:167–79.PubMedPubMedCentralCrossRef
95.
Melamed Z, López-Erauskin J, Baughn MW, et al. Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration. Nat Neurosci. 2019;22:180–90.PubMedPubMedCentralCrossRef
96.
Prudencio M, Humphrey J, Pickles S, et al. Truncated stathmin-2 is a marker of TDP-43 pathology in frontotemporal dementia. J Clin Invest. 2020;130(11): e139741.CrossRef
97.
Ighodaro ET, Jicha GA, Schmitt FA, et al. Hippocampal sclerosis of aging can be segmental: two cases and review of the literature. J Neuropathol Exp Neurol. 2015;74(7):642–52.PubMedCrossRef
Metadata
Title
Limbic-Predominant Age-Related TDP-43 Encephalopathy: LATE-Breaking Updates in Clinicopathologic Features and Biomarkers
Authors
Michael Tran Duong
David A. Wolk
Publication date
03-10-2022

Other articles of this Issue 11/2022

Current Neurology and Neuroscience Reports 11/2022 Go to the issue

Dementia (K.S. Marder, Section Editor)

Vascular Considerations for Amyloid Immunotherapy

Stroke (B. Ovbiagele, Section Editor)

Promise of Physiological Profiling to Prevent Stroke in People of African Ancestry: Prototyping Ghana

Stroke (B. Ovbiagele, Section Editor)

Reversing the Ruin: Rehabilitation, Recovery, and Restoration After Stroke

Dementia (K.S. Marder, Section Editor)

Cognitive and Neuropsychiatric Impairment in Dystonia

Stroke (B. Ovbiagele, Section Editor)

Pre-diabetes, Diabetes, Hyperglycemia, and Stroke: Bittersweet Therapeutic Opportunities

Demyelinating Disorders (J. Bernard and M. Cameron, Section Editors)

Bruton’s Tyrosine Kinase Inhibition in Multiple Sclerosis